Difference Between CGHS and Non-CGHS Diagnostic Rates: A Comparative Analysis

For pathology labs, finance teams, and clinicians, rate structures mean far more than billing. They influence test menus, referrals, documentation, accreditation, and other aspects. In India, one recurring question at the centre of that discussion is the difference between CGHS and non-CGHS diagnostic rates.

CGHS schedules are benchmark-driven and payer-controlled, while private pricing is driven by demand, technology, brand, and service.

Public CGHS rate lists also show separate rate columns for non-NABH/non-NABL and NABH/NABL providers in several city schedules. CGHS empanelment rules also state that accredited rates apply only to tests covered by that accreditation.

Difference Between CGHS and Non-CGHS Diagnostic Rates

Parameter	CGHS-linked diagnostics	Non-CGHS diagnostics
Price setting	Fixed or notified schedule	The lab or hospital decides the rate
Rate flexibility	Low	High
Impact of locality	Limited within the notified framework	Strong impact by city, locality, and competition
Role of accreditation	Separate NABH/NABL rate categories may apply	Can shape brand premium and pricing power
Negotiation space	Restricted	Broad, based on contracts and market position
Documentation burden	High, with strict claim alignment	Varies by payer and internal SOP
Patient payment pattern	Reimbursement or scheme-linked	Mostly self-pay, corporate, TPA, or insurer-linked
Margin strategy	Volume and process discipline matter more	Mix of margin, brand, and service differentiation

The difference between CGHS and non-CGHS diagnostic rates starts with how each rate is created.

CGHS rates are set within an administratively fixed framework across empanelled providers and listed tests.

They are designed for standardisation, reimbursement, and consistency across central government health scheme hospitals and empanelled centres.

By contrast, private or market rates are set by individual providers or chains. They are based on cost structure, competition, city, technology, physician network, turnaround, and patient experience. CGHS schedules also distinguish accredited and non-accredited rates.

The difference between CGHS and non-CGHS diagnostic rates becomes more apparent when a lab compares the same test across payment channels.

A glucose test, viral marker, imaging, or procedure-linked pathology component may carry one notified reimbursement ceiling under CGHS and a very different selling price in the open market.

Published CGHS schedules for cities such as Kolkata and Shillong show separate “Non-NABH/Non-NABL” and “NABH/NABL” columns for many services and tests.

Why the Gap Exists

The main driver behind the difference between CGHS and non-CGHS diagnostic rates is intent.

CGHS pricing is built to control public expenditure and maintain a standard purchase framework. It does not fully mirror the commercial realities faced by all pathology labs in India. For example, labs investing in automation, molecular platforms, digital operations, extended hours, or aggressive logistics. Non-CGHS pricing absorbs those variables directly.

A second driver is accreditation. NABL confirms accreditation for medical laboratories under ISO 15189.

That status carries operational and quality implications for medical laboratories. In CGHS schedules, accredited providers may receive a distinct rate line, which means NABL labs can fit into a higher notified category for eligible services.

In the private market, NABL accreditation may strengthen trust and confidence in referrals. Yet the final selling price still depends on positioning and competition.

A third driver is service packaging. Non-CGHS pricing may bundle convenience, home collection, fast TAT, dashboards, pathologist consult time, or premium patient experience into the final rate. CGHS reimbursement is less elastic on such add-ons.

What It Means For Lab Operations

For lab owners and pathologists, the difference between CGHS and non-CGHS diagnostic rates affects daily operations in real ways.

Profitability varies by payer: Tests that generate strong margins in self-pay cases may produce lower margins under CGHS rates. Labs must track contribution margins by test, analyser line, department, and referral.

Service menu decisions shift: Labs serving many CGHS patients may focus on cost control, reagent standardisation, reduced repeat tests, and strong pre-analytics.

Flexibility in Private-pay segments: Labs targeting walk-in patients, physicians, and corporate accounts can introduce premium diagnostics and bundled packages.

Proper Documentation: CGHS claims require precise coding, referral validation, and compliance with billing categories.

Accreditation affects reimbursement: NABH or NABL rates apply only to tests included within the laboratory’s accredited scope.

Claim delays impact cash flow: errors in documentation or category mismatches can delay payments and disrupt revenue cycles.

Operational discipline: Labs working with CGHS must maintain structured processes across registration, testing, reporting, and claim submission.

Where Professionals Misread The Comparison

• Lower CGHS notified rates do not indicate lower diagnostic quality; they reflect a government-controlled reimbursement model.
• The difference between CGHS and non-CGHS diagnostic rates comes from two different payment frameworks, not from differences in laboratory standards.
• Treating accredited vs non-accredited categories as branding is inaccurate; accreditation directly affects reimbursement classification in CGHS schedules.
• NABL accreditation influences referral trust among hospitals, consultants, and institutional buyers.
• CGHS rate lists separate accredited and non-accredited providers, which impacts how services are reimbursed.
• Comparing CGHS list prices with private market prices without operational context leads to incorrect conclusions.
• Private labs may charge higher prices due to extended staffing, advanced diagnostic technology, middleware systems, quality control protocols, logistics networks, and customer support services.
• The difference between CGHS and non-CGHS diagnostic rates should always be evaluated alongside cost-to-serve and operational structure.

What Labs Should Track Before Setting Prices

Instead of debating rates in the abstract, lab leaders should map five live variables.

• Payer mix by volume and revenue.
• Margin by test and by channel.
• Accredited versus non-accredited service scope.
• Claim rejection or delay trends.
• Local competitor pricing for comparable service levels.

That approach turns the difference between CGHS and non-CGHS diagnostic rates into a management metric rather than a policy.

For multi-site groups, rate governance should be inside one commercial framework. A lab information system or diagnostic SaaS stack should display channel-wise pricing, contract logic, turnaround, and collection efficiency on a single screen.

Final Take

The difference between CGHS and non-CGHS diagnostic rates is a business, compliance, and quality question. CGHS rates follow a standardised reimbursement model. It is related to schedules, empanelment rules, and accreditation.

For pathologists, CFOs, and lab directors, the best way to read the difference between CGHS and non-CGHS diagnostic rates is simple: one rate responds to policy discipline, the other to market discipline. Labs that track both with precision are in a better position to scale with confidence.